What Actually Happened

On December 3, 2024, the VA announced it would fund a study on MDMA-assisted therapy for veterans suffering from both PTSD and alcohol use disorder, according to the official VA press release on news.va.gov. This is the first VA-funded study on psychedelic-assisted therapy since the 1960s.

The grant is $1.5 million over five years.

Who's Running It and Where

Researchers affiliated with Brown University and Yale University will lead the work, according to news.va.gov. The trial will take place at two facilities: the Providence VA Medical Center in Rhode Island and the West Haven VA Medical Center in Connecticut.

Enrollment was anticipated to begin in fiscal year 2025. The study will enroll approximately 80 veterans, according to Newsweek.

How the Trial Works

This is a randomized, placebo-controlled trial — the gold standard for clinical research. Participants receive structured psychotherapy sessions alongside either MDMA or an active placebo, which the VA specifies is a lower dose of MDMA rather than a sugar pill.

MDMA is believed to increase emotional openness, reduce fear, and promote introspection during therapy sessions, according to the VA. The idea isn't to get veterans high — it's to make talk therapy more effective for people who've built up walls that traditional therapy can't break through.

Pharmaceutical-grade MDMA will be used under strict clinical protocols, not street-level product. Everyone will be closely monitored.

Why This Matters

PTSD is one of the most persistent and deadly problems facing American veterans. Existing treatments — antidepressants, cognitive behavioral therapy, EMDR — don't work for everyone. A significant portion of veterans with severe PTSD see little to no improvement from standard-of-care options.

Veteran suicide remains a national crisis. When conventional medicine fails, researchers turn to other options to explore.

The Disabled American Veterans (DAV), a credible veterans' advocacy organization representing over one million members, supports the research. Their membership has approved a resolution backing legislation that directs the VA to study psychedelics and, if effective, make treatments available to veterans with mental health conditions and traumatic brain injury, according to the DAV.

The Regulatory Reality Check

MDMA is still a Schedule I controlled substance under federal law — meaning the government officially classifies it as having high abuse potential and no accepted medical use.

In 2024, the FDA declined to approve MDMA-assisted therapy for PTSD, according to Newsweek. The agency cited concerns about study design and data quality from prior trials conducted by the nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies).

The VA study is trying to generate the rigorous evidence that previous research failed to produce. The use of an active placebo (low-dose MDMA) attempts to address methodological flaws from earlier trials — hard to blind participants when one group feels the drug's effects and the other doesn't.

Political Alignment

VA Secretary Doug Collins, a Trump appointee, publicly endorsed the trial, calling it "an important step in safely evaluating new approaches and innovations to treat Veterans with severe mental health conditions," according to Newsweek. Support for the research crosses typical political lines.

The Bottom Line

The VA is spending $1.5 million to find out whether a controlled, clinical use of MDMA can help veterans that nothing else has helped. The DAV supports it. The research design is sound. The FDA's prior rejection provides reason for rigorous methodology, not abandonment of the effort.

Veterans with treatment-resistant PTSD deserve every legitimate option science can test. If MDMA-assisted therapy works under controlled conditions, the Schedule I classification becomes a bureaucratic obstacle to saving lives. If it doesn't work, the trial tells us that too.